A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

NCT04495257 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Advanced Melanoma
Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: APX005M

Sponsor

Yale University

Collaborators

[object Object]